Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
Public ClinicalTrials.gov record NCT00003172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase II Trial of Either 5-Fluorouracil, Recombinant Alfa-2a-Interferon and Intravenous Hydroxyurea With Filgrastim Support (FHIG) or Doxorubicin/Docetaxel (Dd) in Patients With Advanced Gastric Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different combinations and combining them with interferon alfa and G-CSF may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of different combination chemotherapy regimens in treating patients with advanced stomach cancer.
Study identification
- NCT ID
- NCT00003172
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- filgrastim Biological
- recombinant interferon alfa Biological
- docetaxel Drug
- doxorubicin hydrochloride Drug
- fluorouracil Drug
- hydroxyurea Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1997 (Type not available)
- Primary completion
- Not listed
- Completion
- Sep 2004 (Actual)
- Last update posted
- Jun 21, 2013
1997 – 2004
United States locations
- U.S. sites
- 24
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CCOP - Colorado Cancer Research Program, Inc. | Denver | Colorado | 80209-5031 | — |
| Robert H. Lurie Comprehensive Cancer Center, Northwestern University | Chicago | Illinois | 60611 | — |
| Veterans Affairs Medical Center - Chicago (Lakeside) | Chicago | Illinois | 60611 | — |
| CCOP - Illinois Oncology Research Association | Peoria | Illinois | 61602 | — |
| CCOP - Central Illinois | Springfield | Illinois | 62526 | — |
| CCOP - Cedar Rapids Oncology Project | Cedar Rapids | Iowa | 52403-1206 | — |
| CCOP - Ochsner | New Orleans | Louisiana | 70121 | — |
| New England Medical Center Hospital | Boston | Massachusetts | 02111 | — |
| CCOP - Kalamazoo | Kalamazoo | Michigan | 49007-3731 | — |
| CCOP - Metro-Minnesota | Saint Louis Park | Minnesota | 55416 | — |
| CCOP - Missouri Valley Cancer Consortium | Omaha | Nebraska | 68131 | — |
| Veterans Affairs Medical Center - East Orange | East Orange | New Jersey | 07018-1095 | — |
| CCOP - Northern New Jersey | Hackensack | New Jersey | 07601 | — |
| University of Rochester Cancer Center | Rochester | New York | 14642 | — |
| Albert Einstein Comprehensive Cancer Center | The Bronx | New York | 10461 | — |
| Ireland Cancer Center | Cleveland | Ohio | 44106-5065 | — |
| CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center | Tulsa | Oklahoma | 74136 | — |
| Allegheny University Hospitals- Hahnemann | Philadelphia | Pennsylvania | 19102-1192 | — |
| University of Pennsylvania Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15213 | — |
| CCOP - MainLine Health | Wynnewood | Pennsylvania | 19096 | — |
| Veterans Affairs Medical Center - Madison | Madison | Wisconsin | 53705 | — |
| University of Wisconsin Comprehensive Cancer Center | Madison | Wisconsin | 53792 | — |
| CCOP - Marshfield Medical Research and Education Foundation | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2013 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00003172 live on ClinicalTrials.gov.